A new collaborative drug discovery project on liver cancer at the Institut Pasteur in Korea

On 3 Aug, 2017, Institut Pasteur Korea (IPK, CEO: Dr. Wang-Shick Ryu) and the New Drug Development Center and the Laboratory Animal Center of K-Bio Health signed an MOU for a new drug discovery research collaboration on liver cancer. Despite liver cancer being one of the most frequent cancer globally, there are only a few effective ways to prevent or treat it. Using a 3-dimensional (3D) tumor microenvironment in vitro platform, the Cancer Biology Research Laboratory (CBRL) at IPK has discovered several lead compounds with the potential to fight liver cancer. Under this MOU, three team will set up a liver cancer animal model and test the efficacy of these potential lead compounds.

Find out mores